Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants.
Level II
Where this comes from
- Record sourced from PubMed, PMID 30992220.
- Also identified by DOI 10.1016/j.jpeds.2019.02.029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a phase 1 dose-escalation trial at 2 dosing levels, we assessed the safety of intratracheal administration of a single-dose of human umbilical cord blood-derived mesenchymal stromal cells in 12 extremely low birth weight infants <28 weeks of gestation and <1000 g at birth at 5-14 days of life. The treatment was well tolerated and appears to be safe and feasible, and warrants a larger randomized-controlled blinded study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02381366.
Medical subject headings
- Bronchopulmonary Dysplasia
- Cord Blood Stem Cell Transplantation
- Infant, Extremely Low Birth Weight
- Infant, Premature
- Mesenchymal Stem Cell Transplantation